Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA.
Neuroimage. 2011 Feb 14;54(4):2643-51. doi: 10.1016/j.neuroimage.2010.11.011. Epub 2010 Nov 10.
Previous neuromorphometric investigations of major depressive disorder (MDD) have reported abnormalities in gray matter in several regions, although the results have been inconsistent across studies. Some discrepancies in the results across studies may reflect design limitations such as small sample sizes, whereas others may reflect biological variability that potentially manifests as differences in clinical course. For example, it remains unclear whether the abnormalities found in persistently depressed MDD subjects extend to or persist in patients who experience prolonged remission. The aim of the present study was to investigate gray matter (GM) differences in unmedicated, currently-depressed participants (dMDD) and unmedicated, currently-remitted (rMDD) participants with MDD compared to healthy controls (HC). The GM density and volume were compared across groups using voxel-based morphometry, a quantitative neuroanatomical technique, and high-resolution MRI images from 107 HC, 58 dMDD and 27 rMDD subjects. Relative to the HC group the dMDD group had reduced GM in the dorsal anterolateral (DALPFC), the dorsomedial (DMPFC) and the ventrolateral prefrontal cortex (VLPFC). Relative to the rMDD group the dMDD group showed reduced GM in the DALPFC, the VLPFC, the anterior cingulate cortex (ACC), the precuneus and the inferior parietal lobule. No regions were identified in which the rMDD group showed significantly lower GM compared to the HC group after p-values were corrected for the number of comparisons performed. In unmedicated patients in the depressed phase of MDD, we found evidence of morphometric abnormalities in DALPFC and in medial prefrontal cortical regions belonging to the visceromotor network. These findings, along with the absence of GM abnormalities in the remitted sample imply a possible link between greater GM tissue and better clinical outcome. Consistent with other neuroimaging and post-mortem neuropathological studies of MDD, we also found evidence of decreased white matter in patients with dMDD and rMDD.
先前对重度抑郁症(MDD)的神经形态计量学研究报告称,在几个区域的灰质存在异常,尽管研究结果不一致。研究结果的一些差异可能反映了设计上的限制,如样本量小,而其他差异可能反映了潜在表现为临床病程差异的生物学变异性。例如,目前仍不清楚在持续抑郁的 MDD 患者中发现的异常是否会扩展到或持续存在于经历长时间缓解的患者中。本研究旨在研究未经治疗、目前抑郁的 MDD 患者(dMDD)和未经治疗、目前缓解的 MDD 患者(rMDD)与健康对照组(HC)之间灰质(GM)的差异。使用基于体素的形态计量学比较各组的 GM 密度和体积,这是一种定量神经解剖技术,以及来自 107 名 HC、58 名 dMDD 和 27 名 rMDD 受试者的高分辨率 MRI 图像。与 HC 组相比,dMDD 组在背外侧额前皮质(DALPFC)、背内侧额前皮质(DMPFC)和腹外侧前额叶皮质(VLPFC)的 GM 减少。与 rMDD 组相比,dMDD 组在 DALPFC、VLPFC、前扣带回皮质(ACC)、楔前叶和下顶叶皮层的 GM 减少。在 rMDD 组中,与 HC 组相比,没有发现 GM 显著减少的区域,这是在对进行的比较次数进行 p 值校正后得出的。在 MDD 抑郁期未经治疗的患者中,我们发现 DALPFC 和属于内脏运动网络的内侧前额皮质区域存在形态异常的证据。这些发现,以及缓解样本中 GM 异常的缺失,意味着 GM 组织较多与更好的临床结局之间可能存在联系。与 MDD 的其他神经影像学和死后神经病理学研究一致,我们还发现 dMDD 和 rMDD 患者的白质减少的证据。